Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRUITS: Phase I study of fruquintinib plus trifluridine-tipiracil in unresectable metastatic colorectal cancer
jRCT1031250723Phase 1Recruiting
- Sponsor
- MD Anderson Department of Gastrointestinal Medical Oncology
- Start
- Feb 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fruquintinib and trifluridine + tipiracil in colorectal adenocarcinoma, sponsored by MD Anderson Department of Gastrointestinal Medical Oncology. Primary endpoint: Incidence of Dose-Limiting Toxicities. Started Feb 2026; status: recruiting.
02
Drugs
fruquintinibtrifluridine + tipiracil
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on jRCT1031250723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031250723.